Press Releases

Back to previous page

ReGen Biologics Reports First Bilateral CMIâ„¢ Procedure

FRANKLIN LAKES, NJ -- May 1, 2006 -- ReGen Biologics, Inc. (OTC:RGBI)   A patient with injuries to both the lateral and medial meniscus of the same knee was the recipient of two CMI devices in a first-of-its-kind surgery.  The procedure was performed by Dr. Ricardo Crespo in “La Mancha Centro” General Hospital of Alcázar de San Juan (Ciudad Real).  Assisting in the surgery were William Rodkey, DVM and Dr. Jose L. Sobas.  The procedure was part of a post-market surveillance study that ReGen is conducting in several countries throughout Europe prior to a full European launch of the CMI device for the lateral meniscus.

 The CMI is a collagen scaffold which guides tissue remodeling in the injured meniscus after partial meniscectomy.  The company has been marketing the CMI for use in the medial meniscus for the past five years, and recently received EU approval for an expanded label to include use in the lateral meniscus.

Commenting on the surgery, Dr. Crespo said, “We’re very pleased to have access to a technology that allows us to treat a patient in a way that’s never been done before.  The procedure went very well, and we will be following the rehabilitation process closely to assess the patient’s return to normal activity.  This is a great opportunity for ‘La Mancha Centro’ General Hospital of Alcázar de San Juan.”

A full text Spanish article and accompanying photo can be viewed at http://www.jccm.es/prensa/nota.phtml?cod=17620.

About ReGen Biologics, Inc.
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  The Company’s first approved product using its collagen scaffold technology is the CMI™, which is cleared for sale in Europe and marketed through the Company’s European subsidiary ReGen Biologics AG.

ReGen is headquartered in Franklin Lakes, NJ and manufactures its collagen scaffold products in its ISO Certified facility located in Redwood City, CA.  For more information on ReGen, visit www.regenbio.com.

Contacts:
ReGen Biologics, Inc.
Brion Umidi
Chief Financial Officer
(201) 651-3515
bumidi@regenbio.com

Cameron Associates
Al Palombo
Investor Relations
(212) 554-5488
al@cameronassoc.com

ReGen Biologics, AG
Thomas B. Fischer
Appenzell, Switzerland
+41 (0) 79 500 79 54
thomas.fischer@regenbio.com